A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH, Velez D, Cho E, Cowen EW, DiGiovanna JJ, Pastrana DV, Buck CB, Calvo KR, Gardner PJ, Rosenzweig SD, Stratton P, Merideth MA, Kim HJ, Brewer C, Katz JD, Kuhns DB, Malech HL, Follmann D, Fay MP, Murphy PM.
McDermott DH, et al.
J Clin Invest. 2023 Oct 2;133(19):e164918. doi: 10.1172/JCI164918.
J Clin Invest. 2023.
PMID: 37561579
Free PMC article.
Clinical Trial.
Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associated with lymphopenia and monocytopenia. ...The treatment order was randomized for each patient.RESULTSPlerixafor was nonsuperior to G-CSF for TISS (P …
Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associated with lymphope …